News
IVIXF
0.0018
NaN%
--
Invion Sets Out 2026 Governance Framework and Board Changes
TipRanks · 08/26 08:08
Invion Narrows Annual Loss but Net Tangible Assets Slide Deeper Into Negative Territory
TipRanks · 08/26 08:07
Invion Appoints New Director With No Current Securities Interests
TipRanks · 08/20 04:44
Invion strengthens clinical leadership and expands Photosoft into new cancer and eye indications
TipRanks · 07/31 03:17
Invion Issues New Tranches of Unquoted Options to Strengthen Capital Structure
TipRanks · 06/22 01:08
Invion Seeks ASX Quotation for New Series of Options
TipRanks · 06/22 01:07
Invion boosts PDT push with appointment of global clinical leader Colin Hopper
TipRanks · 06/21 23:52
Invion boosts director equity stake with new incentive options
TipRanks · 06/19 00:58
Invion Issues 671,882 Unquoted Convertible Notes as Part of Funding Strategy
TipRanks · 06/16 11:39
Invion secures strong shareholder backing for capital measures at EGM
TipRanks · 05/29 07:27
Invion corrects director shareholding disclosure in ASX filing
TipRanks · 05/11 06:49
Invion Options Lapse, Trimming Potential Future Dilution
TipRanks · 05/01 04:57
Invion bolsters funding as Photosoft cancer programs show promising progress
TipRanks · 04/30 02:04
Invion convenes virtual general meeting to vote on fair and reasonable transaction
TipRanks · 04/28 01:07
Invion to Showcase Photodynamic Cancer Therapy at Major Asian Biotech Conferences
TipRanks · 04/21 23:07
Invion Expands INV043 Skin Cancer Trial to Basal Cell Carcinoma After Strong Safety Data
TipRanks · 04/21 00:05
Invion Updates Director Interest Disclosure to Strengthen Governance
TipRanks · 04/20 02:37
Invion Updates Market on Director Chiat Thian Chew’s Expanded Associated Holdings
TipRanks · 04/20 02:23
Invion Plans New Issue of 3.2 Million Options on ASX
TipRanks · 03/23 00:27
Invion Plans Share and Option Issue to Strengthen Capital Base
TipRanks · 03/23 00:18
More
Webull provides a variety of real-time IVIXF stock news. You can receive the latest news about Invion Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IVIXF
Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.